Analysis | Incremental QALY gain | Incremental cost | ICER |
---|---|---|---|
Scenario 1: 12-month time horizon, EQ-5D levels in HA group persist from 6 months | 0.056 | US$1707 | US$30,275 |
Scenario 2: 12-month time horizon, HA patients receive a second injection and get the same change in EQ-5D for the second 6 months | 0.043 | US$832 | US$19,316 |
Scenario 3: 6-month time horizon, single office-based GNB and HA injection (assumes CRFA is administered in non-office outpatient facility setting) | 0.020 | US$1422 | US$71,314 |
Scenario 4: 12-month time horizon, HA patients cross over to CRFA at 6 months | 0.025 | -US$875 | CRFA is dominant |